logo

For the Inventor, By the Inventor

Luebeck, Germany

Jan Schmielau

This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignee: University of Pittsburgh. Active years: 2010-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jan Schmielau. Retrieved from https://idiyas.com/inventor/jan-schmielau

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 

% Patents Active = 66.7

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 56(Granted Patents)


Location History:

  • Lübeck, DE (2010)
  • Lubeck, DE (2016 - 2022)

Company Filing History:

goldMedal3 out of 1,960 
 
University of Pittsburgh
 patents

Years Active: 2010-2022

Loading Chart...
3 patents (USPTO):Explore Patents
1. 11325962 - Therapeutic and diagnostic cloned MHC-unrestricted receptor specific for the MUC1 tumor associated antigen (2022-05-10),
2. 9469684 - Therapeutic and diagnostic cloned MHC-unrestricted receptor specific for the MUC1 tumor associated antigen (2016-10-18),
3. 7655461 - Therapeutic and diagnostic cloned MHC-unrestricted receptor specific for the MUC1 tumor associated antigen (2010-02-02),

Title: Jan Schmielau: Innovator in Cancer Therapeutics

Introduction

Jan Schmielau is a notable inventor based in Luebeck, Germany. He has made significant contributions to the field of cancer therapeutics, holding a total of 3 patents. His work focuses on developing innovative solutions for cancer treatment, particularly through the use of specific receptors that target tumor-associated antigens.

Latest Patents

One of Jan Schmielau's latest patents is centered around a therapeutic and diagnostic cloned MHC-unrestricted receptor specific for the MUC1 tumor-associated antigen. This invention provides an isolated nucleic acid encoding a receptor, which is not an immunoglobulin, that binds to the MUC1 tumor antigen independently of a major histocompatibility complex (MHC). The invention also outlines a method for activating a signaling pathway and/or killing a cancer cell using a receptor that is similar to or is a T cell receptor. This innovative approach has the potential to enhance cancer treatment strategies significantly.

Career Highlights

Jan Schmielau is affiliated with the University of Pittsburgh, where he continues to advance his research in cancer therapeutics. His work has garnered attention for its potential impact on improving cancer treatment outcomes.

Collaborations

Jan has collaborated with esteemed colleagues such as Olivera J Finn and Nehad M Alajez, contributing to a rich environment of innovation and research in the field of cancer therapeutics.

Conclusion

Jan Schmielau's contributions to cancer research through his patents and collaborations highlight his commitment to advancing medical science. His innovative approaches have the potential to make a significant difference in the lives of cancer patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…